Paloma Martín-Sanz, Lisardo Boscá, Department of Metabolism and Cell Signaling, Institute of Biomedical Research Alberto Sols, Madrid 28029, Spain.
World J Gastroenterol. 2017 May 28;23(20):3572-3580. doi: 10.3748/wjg.v23.i20.3572.
The biosynthesis of prostaglandins and thromboxanes has been a focus of interest in the management of many liver diseases. Cyclooxygenases are the enzymes involved in the first step of the biosynthesis of these lipid mediators and selective inhibitors for these isoenzymes as well as pharmacological analogues of prostaglandins have been developed and are currently applied therapeutically. Here we discuss the implications of these enzymes in the onset of metabolic and lipid disorders in the liver and their potential role in the progression of the diseases towards fibrosis and hepatocellular carcinogenesis.
前列腺素和血栓素的生物合成一直是许多肝脏疾病治疗的关注焦点。环氧化酶是这些脂类介质生物合成的第一步所涉及的酶，这些同工酶的选择性抑制剂以及前列腺素的药理学类似物已经被开发出来，并正在临床上应用。在这里，我们讨论了这些酶在肝脏代谢和脂质紊乱发病机制中的作用及其在疾病向纤维化和肝细胞癌发展过程中的潜在作用。
